New minor risk - Share price stability Mar 01
Co-Founder recently sold CA$98k worth of stock Jan 29
BioNxt Solutions Inc. Reports Final Preclinical Results Demonstrating Approximately 40% Higher Cladribine Delivery Jan 22
Third quarter 2025 earnings released: CA$0.014 loss per share (vs CA$0.013 loss in 3Q 2024) Nov 30
Co-Founder recently sold CA$55k worth of stock Nov 20
New minor risk - Insider selling Nov 20
Co-Founder recently sold CA$55k worth of stock Nov 19
New minor risk - Share price stability Sep 15
BioNxt Solutions Inc., Annual General Meeting, Nov 07, 2025 Sep 08
First half 2025 earnings released: CA$0.028 loss per share (vs CA$0.023 loss in 1H 2024) Aug 31
BioNxt Solutions Inc. announced that it expects to receive CAD 1.2 million in funding Jul 13
New major risk - Financial position Jun 27
First quarter 2025 earnings released: CA$0.017 loss per share (vs CA$0.014 loss in 1Q 2024) Jun 27
New minor risk - Financial data availability Jun 17
New major risk - Market cap size May 06
BioNxt Solutions Inc. announced that it has received CAD 2.5 million in funding Mar 15
BioNxt Solutions Inc. announced that it expects to receive CAD 2.5 million in funding Feb 25
BioNxt Solutions Inc. announced that it has received CAD 3 million in funding Jan 15
BioNxt Solutions Inc. Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment Dec 09
Third quarter 2024 earnings released: CA$0.013 loss per share (vs CA$0.014 loss in 3Q 2023) Dec 01
BioNxt Solutions Inc. Announces Enhanced Sublingual Product Development Pipeline with Innovative Solutions for Autoimmune Diseases and Longevity Nov 26
BioNxt Solutions Inc. announced that it expects to receive CAD 3 million in funding Oct 29
Bionxt Solutions Inc. Provides Update on Cladribine Program for Multiple Sclerosis, Sublingual Neurodegenerative Disease Patent Sep 26
BioNxt Solutions Inc. Receives Positive International Examination Report from the European Patent Office for Broad Patent Application for Sublingual Delivery of Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases Sep 11
BioNxt Solutions Inc., Annual General Meeting, Nov 01, 2024 Sep 03
Second quarter 2024 earnings released: CA$0.009 loss per share (vs CA$0.024 loss in 2Q 2023) Aug 29
New major risk - Share price stability Aug 20
BioNxt Solutions Inc. announced that it has received CAD 0.945 million in funding Jun 28
First quarter 2024 earnings released: CA$0.014 loss per share (vs CA$0.016 loss in 1Q 2023) Jun 04
Full year 2023 earnings released: CA$0.078 loss per share (vs CA$0.15 loss in FY 2022) Apr 23
BioNxt Solutions Inc. Reports Commercialization of Odf Cladribine Product for MS Next Steps Mar 20
BioNxt Solutions Inc. Reports Successful Results from ODF Cladribine PK Study Mar 13
BioNxt Solutions Inc. Reports Successful Results from Odf Cladribine Toxicity Study Feb 07
BioNxt Solutions Inc. announced that it has received CAD 1.168 million in funding Jan 30
BioNxt Solutions Inc. announced that it expects to receive CAD 2.4 million in funding Dec 23
BioNxt Solutions Announces Completion of Cladribine ODF Toxicity Study and Financing Dec 22
Third quarter 2023 earnings released: CA$0.014 loss per share (vs CA$0.023 loss in 3Q 2022) Nov 24
BioNxt Solutions Inc Reports on New Cladrabine Odf Product Development and Commercialization Program Nov 17
BioNxt Solutions Inc. Announces Change of Directors Oct 05
Second quarter 2023 earnings released: CA$0.024 loss per share (vs CA$0.017 loss in 2Q 2022) Aug 31
BioNxt Solutions Inc. announced that it expects to receive CAD 3.975 million in funding Aug 07
New minor risk - Share price stability Jun 26
First quarter 2023 earnings released: CA$0.016 loss per share (vs CA$0.023 loss in 1Q 2022) May 31
Bionxt Solutions Inc. Receives Approval for European Clinical Study of Transdermal Rotigotine Patch for Parkinson's Disease May 15
Full year 2022 earnings released: CA$0.15 loss per share (vs CA$0.29 loss in FY 2021) Apr 13
BioNxt Solutions Inc. Reports Update on Commercialization of Rotigotine Patch for Treatment of Parkinson's Disease Feb 13
BioNxt Solutions Inc. announced that it has received CAD 2.808 million in funding Dec 08
BioNxt Solutions Inc. announced that it expects to receive CAD 2.6 million in funding Nov 30
Third quarter 2022 earnings released: CA$0.023 loss per share (vs CA$0.036 loss in 3Q 2021) Nov 29
Less than half of directors are independent Nov 16
XPhyto Reports Excellent Rotigotine In-Vitro/Ex-Vivo Results for Parkinson's Disease Treatment Oct 18
Xphyto Therapeutics Corp. Completes Rotigotine Transdermal Patch Optimization and Comparative Skin Absorption Study Oct 12
XPhyto Therapeutics Corp. Files Patent Application for Library of Novel Psychedelic Compounds Sep 20
XPhyto Therapeutics Corp. announced that it has received CAD 3.6 million in funding Sep 03
Second quarter 2022 earnings released: CA$0.017 loss per share (vs CA$0.061 loss in 2Q 2021) Aug 27
XPhyto Therapeutics Corp., Annual General Meeting, Oct 12, 2022 Aug 13
XPhyto Therapeutics Corp. announced that it expects to receive CAD 3.6 million in funding Jul 23
Xphyto Pursues Potential Application of its Oral Dissolvable Biosensor Inflammation Test for Buprenorphine-Related Dental Disease Jul 19
Xphyto Therapeutics Corp. Adds Dr. Flon A. Sahr to Its European Teateam as Head of Project Management Jun 10
Full year 2021 earnings released: CA$0.29 loss per share (vs CA$0.29 loss in FY 2020) May 01
Less than half of directors are independent Apr 27
President recently sold CA$184k worth of stock Mar 23
President exercised options to buy CA$357k worth of stock. Mar 21
XPhyto Therapeutics Corp. (CNSX:XPHY) completed the acquisition of 3a-diagnostics GmbH. Dec 07
Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat Nov 28
XPhyto Therapeutics Corp. announced that it has received CAD 7 million in funding Nov 27
Second quarter 2021 earnings released: CA$0.061 loss per share (vs CA$0.064 loss in 2Q 2020) Aug 28
Director Peter Damouni has joined 7th company board Aug 07
Director Peter Damouni has joined 7th company board Aug 07
Director Peter Damouni has joined 7th company board Aug 07
Director Peter Damouni has joined 7th company board Aug 07